Sign up to save your podcasts
Or
Share NEJM at ESMO — Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NEJM at ESMO — Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
View all episodes
By NEJM Group
4.4
120120 ratings
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
More shows like NEJM Interviews
View all
JAMA Editors' Summary
137 Listeners
NEJM This Week
317 Listeners
JAMA Clinical Reviews
498 Listeners
JACC This Week
169 Listeners
Clinical Conversations
57 Listeners
Mayo Clinic Talks
298 Listeners
BMJ Best Practice Podcast
22 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
137 Listeners
Core IM | Internal Medicine Podcast
1,145 Listeners
Curbside Consults
92 Listeners
Leadership Conversations
5 Listeners
Annals On Call Podcast
195 Listeners
JAMA Medical News
92 Listeners
The Clinical Problem Solvers
515 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
367 Listeners
Cardionerds: A Cardiology Podcast
426 Listeners
The Curious Clinicians
370 Listeners
NEJM AI Grand Rounds
60 Listeners
Intention to Treat
31 Listeners
Not Otherwise Specified
67 Listeners